Thermo Fisher Scientific Inc. (TMO) ranks 76th in market activity with $884 million trading volume

On May 20, 2025, Thermo Fisher Scientific Inc. (TMO) experienced a slight decline of 0.04%, with a trading volume of $884 million, ranking 76th in the day's market activity.

Analysts have set an average target price of $570.17 for Thermo Fisher Scientific Inc. (TMO), suggesting a potential upside of 38.37% from the current stock price of $414 per share. This optimistic outlook is supported by the company's strong fundamentals and growth prospects.

Thermo Fisher Scientific Inc. (TMO) is expected to report its next earnings release on July 23, 2025. Analysts anticipate earnings of $5.22 per share for the upcoming release, reflecting the company's robust financial performance and growth trajectory.

Despite the strong stock market rally, analysts caution about potential volatility in early 2025, which could impact Thermo Fisher Scientific Inc. (TMO) and other stocks in the market. Investors are advised to stay vigilant and monitor market conditions closely.

Thermo Fisher Scientific Inc. (TMO) is projected to grow its earnings per share (EPS) by 27% over the next three years, driven by factors such as biopharma and pharmaceutical recovery, precision medicine expansion, operational efficiency initiatives, strategic M&A, and China recovery. This growth is expected to accelerate after a period of normalization in 2024-2025.

Thermo Fisher Scientific Inc. (TMO) stock is currently trading at a forward P/E multiple of 18x, which is below its 10-year historical average of 22x. This lower valuation presents a value opportunity for investors, as the company's strong fundamentals and growth prospects justify a higher valuation.

Analysts have an average price target of around $570 per share for Thermo Fisher Scientific Inc. (TMO) stock, indicating a potential 38% upside from the current share price. This bullish outlook is supported by the company's substantial competitive advantages, technological leadership, and consistent execution.

Investors should be aware of several risks that could impact Thermo Fisher Scientific Inc. (TMO)'s growth trajectory, including persistent biopharma weakness, competitive pressure, integration challenges, currency headwinds, and regulatory environment changes. These risks could delay the expected growth acceleration and impact the company's financial performance.